{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T21:06:22Z","timestamp":1793480782244,"version":"4.5.0"},"reference-count":116,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bcp.2025.117275","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T15:50:39Z","timestamp":1755877839000},"page":"117275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"P1","title":["Glutaminase 1 inhibitors: Therapeutic potential, mechanisms of action, and clinical perspectives"],"prefix":"10.1016","volume":"242","author":[{"given":"Hui","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiandeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bcp.2025.117275_b0005","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.bcp.2025.117275_b0010","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/nrc.2016.71","article-title":"From Krebs to clinic: glutamine metabolism to cancer therapy","volume":"16","author":"Altman","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2025.117275_b0015","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.cmet.2011.12.009","article-title":"Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells","volume":"15","author":"Le","year":"2012","journal-title":"Cell Metab."},{"issue":"5","key":"10.1016\/j.bcp.2025.117275_b0020","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1101\/gad.1756509","article-title":"Tumor suppressors and cell metabolism: a recipe for cancer growth","volume":"23","author":"Jones","year":"2009","journal-title":"Genes Dev."},{"key":"10.1016\/j.bcp.2025.117275_b0025","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1146\/annurev.nu.15.070195.001025","article-title":"Regulation of glutaminase activity and glutamine metabolism","volume":"15","author":"Curthoys","year":"1995","journal-title":"Annu. Rev. Nutr."},{"issue":"4","key":"10.1016\/j.bcp.2025.117275_b0030","doi-asserted-by":"crossref","first-page":"514","DOI":"10.2174\/1566524011313040005","article-title":"Glutaminase isoenzymes as key regulators in metabolic and oxidative stress against cancer","volume":"13","author":"Mat\u00e9s","year":"2013","journal-title":"Curr. Mol. Med."},{"issue":"2","key":"10.1016\/j.bcp.2025.117275_b0035","doi-asserted-by":"crossref","first-page":"223","DOI":"10.4155\/fmc-2016-0190","article-title":"A tale of two glutaminases: homologous enzymes with distinct roles in tumorigenesis","volume":"9","author":"Katt","year":"2017","journal-title":"Future Med. Chem."},{"issue":"12","key":"10.1016\/j.bcp.2025.117275_b0040","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.4161\/cbt.21348","article-title":"Analysis of glutamine dependency in non-small cell lung cancer: GLS1 splice variant GAC is essential for cancer cell growth","volume":"13","author":"van den Heuvel","year":"2012","journal-title":"Cancer Biol. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2025.117275_b0045","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.bbrc.2018.08.069","article-title":"c-Myc-driven glycolysis via TXNIP suppression is dependent on glutaminase-MondoA axis in prostate cancer","volume":"504","author":"Qu","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"10","key":"10.1016\/j.bcp.2025.117275_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100828","article-title":"Combined blockade of EGFR and glutamine metabolism in preclinical models of colorectal cancer","volume":"13","author":"Cohen","year":"2020","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.bcp.2025.117275_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112980","article-title":"Discovery and optimization of withangulatin A derivatives as novel glutaminase 1 inhibitors for the treatment of triple-negative breast cancer","volume":"210","author":"Zhou","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117275_b0060","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ebiom.2018.11.063","article-title":"Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt\/beta-catenin pathway","volume":"39","author":"Li","year":"2019","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.bcp.2025.117275_b0065","first-page":"1915","article-title":"Expression of GLS1 in intrahepatic cholangiocarcinoma and its clinical significance","volume":"20","author":"Cao","year":"2019","journal-title":"Mol. Med. Rep."},{"issue":"10","key":"10.1016\/j.bcp.2025.117275_b0070","first-page":"4265","article-title":"Glutaminase inhibitor compound 968 inhibits cell proliferation and sensitizes paclitaxel in ovarian cancer","volume":"8","author":"Yuan","year":"2016","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.bcp.2025.117275_b0075","doi-asserted-by":"crossref","unstructured":"L. Ren, V. Ruiz-Rodado, T. Dowdy, S. Huang, S.H. Issaq, J. Beck, H. Wang, C. Tran Hoang, A. Lita, M. Larion, A.K. LeBlanc, Glutaminase-1 (GLS1) inhibition limits metastatic progression in osteosarcoma, Cancer Metab. 8 (2020) 4. doi:10.1186\/s40170-020-0209-8.","DOI":"10.1186\/s40170-020-0209-8"},{"issue":"4","key":"10.1016\/j.bcp.2025.117275_b0080","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.exphem.2013.12.001","article-title":"Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations","volume":"42","author":"Emadi","year":"2014","journal-title":"Exp. Hematol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117275_b0085","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1038\/s41598-019-41523-4","article-title":"Targeting cellular metabolism to reduce head and neck cancer growth","volume":"9","author":"Yang","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2025.117275_b0090","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40170-015-0137-1","article-title":"Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by \u00df-lapachone","volume":"3","author":"Chakrabarti","year":"2015","journal-title":"Cancer Metab."},{"issue":"11","key":"10.1016\/j.bcp.2025.117275_b0095","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1007\/s12094-021-02645-2","article-title":"Targeting GLS1 to cancer therapy through glutamine metabolism","volume":"23","author":"Yu","year":"2021","journal-title":"Clin. Transl. Oncol."},{"issue":"4","key":"10.1016\/j.bcp.2025.117275_b0100","doi-asserted-by":"crossref","first-page":"600","DOI":"10.37349\/etat.2023.00155","article-title":"Aspirin and the metabolic hallmark of cancer: novel therapeutic opportunities for colorectal cancer","volume":"4","author":"Hoskin","year":"2023","journal-title":"Explor. Target Antitumor. Ther."},{"issue":"21","key":"10.1016\/j.bcp.2025.117275_b0105","doi-asserted-by":"crossref","first-page":"4815","DOI":"10.1158\/0008-5472.CAN-20-0600","article-title":"5-fluorouracil enhances the antitumor activity of the glutaminase inhibitor CB-839 against PIK3CA-mutant colorectal cancers","volume":"80","author":"Zhao","year":"2020","journal-title":"Cancer Res."},{"issue":"50","key":"10.1016\/j.bcp.2025.117275_b0110","doi-asserted-by":"crossref","first-page":"10764","DOI":"10.1021\/bi201613d","article-title":"Full-length human glutaminase in complex with an allosteric inhibitor","volume":"50","author":"DeLaBarre","year":"2011","journal-title":"Biochemistry"},{"issue":"20","key":"10.1016\/j.bcp.2025.117275_b0115","doi-asserted-by":"crossref","first-page":"7705","DOI":"10.1073\/pnas.1116573109","article-title":"Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism","volume":"109","author":"Thangavelu","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.bcp.2025.117275_b0120","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1111\/febs.16658","article-title":"A novel allosteric site employs a conserved inhibition mechanism in human kidney-type glutaminase","volume":"290","author":"Shankar","year":"2023","journal-title":"FEBS J."},{"issue":"16","key":"10.1016\/j.bcp.2025.117275_b0125","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168504","article-title":"Mitochondrial metabolism behind region-specific resistance to ischemia-reperfusion injury in gerbil hippocampus. role of PKC\u03b2II and phosphate-activated glutaminase","volume":"22","author":"Ber\u0119sewicz-Haller","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2025.117275_b0130","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1021\/acs.jmedchem.8b00961","article-title":"Overview of the development of glutaminase inhibitors: achievements and future directions","volume":"62","author":"Xu","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117275_b0135","doi-asserted-by":"crossref","unstructured":"A.P. Ferreira, A. Cassago, A. Gon\u00e7alves Kde, M.M. Dias, D. Adamoski, C.F. Ascen\u00e7\u00e3o, R.V. Honorato, J.F. de Oliveira, I.M. Ferreira, C. Fornezari, J. Bettini, P.S. Oliveira, A.F. Paes Leme, R.V. Portugal, A.L. Ambrosio, S.M. Dias, Active glutaminase C self-assembles into a supratetrameric oligomer that can be disrupted by an allosteric inhibitor, J. Biol. Chem. 288(39) (2013) 28009-20. doi:10.1074\/jbc.M113.501346.","DOI":"10.1074\/jbc.M113.501346"},{"issue":"12","key":"10.1016\/j.bcp.2025.117275_b0140","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70131","article-title":"Microenvironmental G protein-coupled estrogen receptor-mediated glutamine metabolic coupling between cancer-associated fibroblasts and triple-negative breast cancer cells governs tumour progression","volume":"14","author":"He","year":"2024","journal-title":"Clin. Transl. Med."},{"issue":"6","key":"10.1016\/j.bcp.2025.117275_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112644","article-title":"20-hydroxyecdysone reprograms amino acid metabolism to support the metamorphic development of Helicoverpa armigera","volume":"42","author":"Wang","year":"2023","journal-title":"Cell Rep."},{"issue":"4","key":"10.1016\/j.bcp.2025.117275_b0150","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1074\/jbc.RA117.000444","article-title":"Glutaminolysis is required for transforming growth factor-\u03b21-induced myofibroblast differentiation and activation","volume":"293","author":"Bernard","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2025.117275_b0155","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jhep.2015.11.018","article-title":"Model-guided identification of a therapeutic strategy to reduce hyperammonemia in liver diseases","volume":"64","author":"Ghallab","year":"2016","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.bcp.2025.117275_b0160","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.bcp.2025.117275_b0165","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11121945","article-title":"GLUL ablation can confer drug resistance to cancer cells via a malate-aspartate shuttle-mediated mechanism","volume":"11","author":"Muthu","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.bcp.2025.117275_b0170","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3892\/etm.2023.12274","article-title":"Glutathione promotes the synergistic effects of venetoclax and azacytidine against myelodysplastic syndrome\u2011refractory anemia by regulating the cell cycle","volume":"26","author":"Wang","year":"2023","journal-title":"Exp. Ther. Med."},{"issue":"5","key":"10.1016\/j.bcp.2025.117275_b0175","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/onc.2012.635","article-title":"Control of glutamine metabolism by the tumor suppressor Rb","volume":"33","author":"Reynolds","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2025.117275_b0180","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.2147\/OTT.S167408","article-title":"Nuclear factor-\u03baB p65 regulates glutaminase 1 expression in human hepatocellular carcinoma","volume":"11","author":"Dong","year":"2018","journal-title":"Onco Targets Ther"},{"issue":"7779","key":"10.1016\/j.bcp.2025.117275_b0185","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41586-019-1678-1","article-title":"Metabolic regulation of gene expression by histone lactylation","volume":"574","author":"Zhang","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2025.117275_b0190","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1080\/15384101.2015.1120930","article-title":"Lactate promotes glutamine uptake and metabolism in oxidative cancer cells","volume":"15","author":"P\u00e9rez-Escuredo","year":"2016","journal-title":"Cell Cycle"},{"issue":"12","key":"10.1016\/j.bcp.2025.117275_b0195","first-page":"3930","article-title":"Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice","volume":"118","author":"Sonveaux","year":"2008","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.bcp.2025.117275_b0200","doi-asserted-by":"crossref","first-page":"G543","DOI":"10.1152\/ajpgi.00418.2012","article-title":"Epidermal growth factor receptor expression and signaling are essential in glutamine's cytoprotective mechanism in heat-stressed intestinal epithelial-6 cells","volume":"304","author":"Niederlechner","year":"2013","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bcp.2025.117275_b0205","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/j.biopha.2018.10.046","article-title":"TCF7L2 activated HOXA-AS2 decreased the glucocorticoid sensitivity in acute lymphoblastic leukemia through regulating HOXA3\/EGFR\/Ras\/Raf\/MEK\/ERK pathway","volume":"109","author":"Zhao","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.bcp.2025.117275_b0210","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ccr.2010.08.009","article-title":"Targeting mitochondrial glutaminase activity inhibits oncogenic transformation","volume":"18","author":"Wang","year":"2010","journal-title":"Cancer Cell"},{"issue":"48","key":"10.1016\/j.bcp.2025.117275_b0215","doi-asserted-by":"crossref","first-page":"18782","DOI":"10.1073\/pnas.0810199105","article-title":"Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction","volume":"105","author":"Wise","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7043","key":"10.1016\/j.bcp.2025.117275_b0220","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nature03677","article-title":"c-Myc-regulated microRNAs modulate E2F1 expression","volume":"435","author":"O'Donnell","year":"2005","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2025.117275_b0225","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/ng.2007.30","article-title":"Widespread microRNA repression by Myc contributes to tumorigenesis","volume":"40","author":"Chang","year":"2008","journal-title":"Nat. Genet."},{"issue":"7239","key":"10.1016\/j.bcp.2025.117275_b0230","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nature07823","article-title":"c-Myc suppression of miR-23a\/b enhances mitochondrial glutaminase expression and glutamine metabolism","volume":"458","author":"Gao","year":"2009","journal-title":"Nature"},{"issue":"6487","key":"10.1016\/j.bcp.2025.117275_b0235","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaw5473","article-title":"Metabolic reprogramming and cancer progression","volume":"368","author":"Faubert","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bcp.2025.117275_b0240","doi-asserted-by":"crossref","unstructured":"M.G. Vander Heiden, L.C. Cantley, C.B. Thompson, Understanding the Warburg effect: the metabolic requirements of cell proliferation, Science 324(5930) (2009) 1029-33. doi:10.1126\/science.1160809.","DOI":"10.1126\/science.1160809"},{"issue":"4","key":"10.1016\/j.bcp.2025.117275_b0245","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.semcdb.2012.02.002","article-title":"Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis","volume":"23","author":"Daye","year":"2012","journal-title":"Semin. Cell Dev. Biol."},{"issue":"10","key":"10.1016\/j.bcp.2025.117275_b0250","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.molcel.2022.03.016","article-title":"Filamentous GLS1 promotes ROS-induced apoptosis upon glutamine deprivation via insufficient asparagine synthesis","volume":"82","author":"Jiang","year":"2022","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.bcp.2025.117275_b0255","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1083\/jcb.200703099","article-title":"Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells","volume":"178","author":"Yuneva","year":"2007","journal-title":"J. Cell Biol."},{"issue":"11","key":"10.1016\/j.bcp.2025.117275_b0260","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc3106","article-title":"RAS oncogenes: weaving a tumorigenic web","volume":"11","author":"Pylayeva-Gupta","year":"2011","journal-title":"Nat. Rev. Cancer"},{"issue":"14","key":"10.1016\/j.bcp.2025.117275_b0265","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1038\/onc.2016.360","article-title":"Tumor-associated mutant p53 promotes cancer cell survival upon glutamine deprivation through p21 induction","volume":"36","author":"Tran","year":"2017","journal-title":"Oncogene"},{"issue":"37","key":"10.1016\/j.bcp.2025.117275_b0270","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1038\/onc.2012.610","article-title":"The mutant p53 mouse as a pre-clinical model","volume":"32","author":"Jackson","year":"2013","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.bcp.2025.117275_b0275","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.bcp.2025.117275_b0280","doi-asserted-by":"crossref","DOI":"10.3390\/nu10111564","article-title":"Glutamine: metabolism and immune function, supplementation and clinical translation","volume":"10","author":"Cruzat","year":"2018","journal-title":"Nutrients"},{"issue":"7508","key":"10.1016\/j.bcp.2025.117275_b0285","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nature13312","article-title":"Metabolism of stromal and immune cells in health and disease","volume":"511","author":"Ghesqui\u00e8re","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2025.117275_b0290","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cbi.2016.06.026","article-title":"Utilization of metabonomics to identify serum biomarkers in murine H22 hepatocarcinoma and deduce antitumor mechanism of Rhizoma Paridis saponins","volume":"256","author":"Qiu","year":"2016","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bcp.2025.117275_b0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2015.00001","article-title":"Glucose metabolism regulates T cell activation, differentiation, and functions","volume":"6","author":"Palmer","year":"2015","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.bcp.2025.117275_b0300","doi-asserted-by":"crossref","DOI":"10.1172\/JCI140100","article-title":"Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer","volume":"131","author":"Edwards","year":"2021","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.bcp.2025.117275_b0305","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.4049\/jimmunol.0903586","article-title":"Glutamine uptake and metabolism are coordinately regulated by ERK\/MAPK during T lymphocyte activation","volume":"185","author":"Carr","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2025.117275_b0310","doi-asserted-by":"crossref","unstructured":"B.I. Reinfeld, M.Z. Madden, M.M. Wolf, A. Chytil, J.E. Bader, A.R. Patterson, A. Sugiura, A.S. Cohen, A. Ali, B.T. Do, A. Muir, C.A. Lewis, R.A. Hongo, K.L. Young, R.E. Brown, V.M. Todd, T. Huffstater, A. Abraham, R.T. O'Neil, M.H. Wilson, F. Xin, M.N. Tantawy, W.D. Merryman, R.W. Johnson, C.S. Williams, E.F. Mason, F.M. Mason, K.E. Beckermann, M.G. Vander Heiden, H.C. Manning, J.C. Rathmell, W.K. Rathmell, Cell-programmed nutrient partitioning in the tumour microenvironment, Nature 593 (7858) (2021) 282-288. doi:10.1038\/s41586-021-03442-1.","DOI":"10.1101\/2020.08.10.238428"},{"issue":"1","key":"10.1016\/j.bcp.2025.117275_b0315","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.bbrc.2013.11.043","article-title":"Small molecule glutaminase inhibitors block glutamate release from stimulated microglia","volume":"443","author":"Thomas","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2025.117275_b0320","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1038\/srep03827","article-title":"Structural basis for the active site inhibition mechanism of human kidney-type glutaminase (KGA)","volume":"4","author":"Thangavelu","year":"2014","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.bcp.2025.117275_b0325","first-page":"6909","article-title":"A combination of inhibitors of glycolysis, glutaminolysis and de novo fatty acid synthesis decrease the expression of chemokines in human colon cancer cells","volume":"18","author":"Schcolnik-Cabrera","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bcp.2025.117275_b0330","article-title":"Glutamine antagonist JHU083 improves psychosocial behavior and sleep deficits in EcoHIV-infected mice","volume":"23","author":"Bell","year":"2022","journal-title":"Brain Behav. Immun. Health"},{"issue":"3","key":"10.1016\/j.bcp.2025.117275_b0335","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s11481-019-09859-w","article-title":"Glutamine antagonist JHU083 normalizes aberrant glutamate production and cognitive deficits in the EcoHIV murine model of HIV-associated neurocognitive disorders","volume":"14","author":"Nedelcovych","year":"2019","journal-title":"J. Neuroimmune Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2025.117275_b0340","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/onc.2009.358","article-title":"Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer","volume":"29","author":"DeBerardinis","year":"2010","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.bcp.2025.117275_b0345","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1021\/bi991797d","article-title":"Reactions of Pseudomonas 7A glutaminase-asparaginase with diazo analogues of glutamine and asparagine result in unexpected covalent inhibitions and suggests an unusual catalytic triad Thr-Tyr-Glu","volume":"39","author":"Ortlund","year":"2000","journal-title":"Biochemistry"},{"issue":"2","key":"10.1016\/j.bcp.2025.117275_b0350","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.bbrc.2013.06.110","article-title":"Kinetic characterization of ebselen, chelerythrine and apomorphine as glutaminase inhibitors","volume":"438","author":"Thomas","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2025.117275_b0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2019.104508","article-title":"Glutaminase activity in GLS1 Het mouse brain compared to putative pharmacological inhibition by ebselen using ex vivo MRS","volume":"129","author":"Kosten","year":"2019","journal-title":"Neurochem. Int."},{"issue":"3","key":"10.1016\/j.bcp.2025.117275_b0360","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1042\/BJ20070039","article-title":"Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES)","volume":"406","author":"Robinson","year":"2007","journal-title":"Biochem. J."},{"issue":"22","key":"10.1016\/j.bcp.2025.117275_b0365","doi-asserted-by":"crossref","first-page":"8981","DOI":"10.1158\/0008-5472.CAN-10-1666","article-title":"Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1","volume":"70","author":"Seltzer","year":"2010","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.bcp.2025.117275_b0370","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1172\/JCI75836","article-title":"Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis","volume":"125","author":"Xiang","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"36","key":"10.1016\/j.bcp.2025.117275_b0375","doi-asserted-by":"crossref","first-page":"E5328","DOI":"10.1073\/pnas.1611406113","article-title":"Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer","volume":"113","author":"Elgogary","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.bcp.2025.117275_b0380","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.bbrc.2016.06.095","article-title":"Glutaminase 1 inhibition reduces thymidine synthesis in NSCLC","volume":"477","author":"Lee","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2025.117275_b0385","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jconrel.2024.05.045","article-title":"Biomimetic copper-doped polypyrrole nanoparticles induce glutamine metabolism inhibition to enhance breast cancer cuproptosis and immunotherapy","volume":"371","author":"Zhang","year":"2024","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.bcp.2025.117275_b0390","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1158\/1535-7163.MCT-11-0942","article-title":"Dibenzophenanthridines as inhibitors of glutaminase C and cancer cell proliferation","volume":"11","author":"Katt","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"11","key":"10.1016\/j.bcp.2025.117275_b0395","article-title":"The glutaminase-1 inhibitor 968 enhances dihydroartemisinin-mediated antitumor efficacy in hepatocellular carcinoma cells","volume":"11","author":"Wang","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.bcp.2025.117275_b0400","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2174\/1871520622666220513163341","article-title":"The glutaminase inhibitor compound 968 exhibits potent in vitro and in vivo anti-tumor effects in endometrial cancer","volume":"23","author":"Guo","year":"2023","journal-title":"Anticancer Agents Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2025.117275_b0405","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41420-021-00590-1","article-title":"Compound 968 reverses adriamycin resistance in breast cancer MCF-7(ADR) cells via inhibiting P-glycoprotein function independently of glutaminase","volume":"7","author":"Yang","year":"2021","journal-title":"Cell Death Discov."},{"issue":"21","key":"10.1016\/j.bcp.2025.117275_b0410","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1182\/blood.V122.21.4226.4226","article-title":"Antitumor activity of the glutaminase inhibitor CB-839 in hematological malignances","volume":"122","author":"Parlati","year":"2013","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.bcp.2025.117275_b0415","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1182\/blood.V126.23.2566.2566","article-title":"Phase 1 study of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase in patients with relapsed\/refractory leukemia","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bcp.2025.117275_b0420","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/1535-7163.MCT-13-0870","article-title":"Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer","volume":"13","author":"Gross","year":"2014","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.bcp.2025.117275_b0425","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-019-1141-0","article-title":"Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer","volume":"21","author":"Grinde","year":"2019","journal-title":"Breast Cancer Res."},{"issue":"3","key":"10.1016\/j.bcp.2025.117275_b0430","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.celrep.2016.12.061","article-title":"Targeted inhibition of EGFR and glutaminase induces metabolic crisis in EGFR mutant lung cancer","volume":"18","author":"Momcilovic","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.bcp.2025.117275_b0435","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.exphem.2017.09.007","article-title":"Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia","volume":"58","author":"Gregory","year":"2018","journal-title":"Exp. Hematol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117275_b0440","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12964-019-0412-9","article-title":"Estrogen inhibits autophagy and promotes growth of endometrial cancer by promoting glutamine metabolism","volume":"17","author":"Zhou","year":"2019","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.bcp.2025.117275_b0445","doi-asserted-by":"crossref","first-page":"686","DOI":"10.3389\/fonc.2019.00686","article-title":"Glutamine metabolism drives growth in advanced hormone receptor positive breast cancer","volume":"9","author":"Demas","year":"2019","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.bcp.2025.117275_b0450","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1080\/09553002.2018.1558299","article-title":"Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice","volume":"95","author":"Boysen","year":"2019","journal-title":"Int. J. Radiat Biol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117275_b0455","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41467-020-14374-1","article-title":"Targeting glutamine metabolism slows soft tissue sarcoma growth","volume":"11","author":"Lee","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2025.117275_b0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176912","article-title":"CB-839 induces reversible dormancy in lung tumor-cells","volume":"982","author":"Jamshidi-Parsian","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117275_b0465","doi-asserted-by":"crossref","unstructured":"S. Varghese, S. Pramanik, L.J. Williams, H.R. Hodges, C.W. Hudgens, G.M. Fischer, C.K. Luo, B. Knighton, L. Tan, P.L. Lorenzi, A.L. Mackinnon, J.L. McQuade, Y. Hailemichael, J. Roszik, W. Peng, Y.N. Vashisht Gopal, The glutaminase inhibitor CB-839 (telaglenastat) enhances the antimelanoma activity of T-Cell-mediated immunotherapies, Mol. Cancer Ther. 20(3) (2021) 500-511. doi:10.1158\/1535-7163.Mct-20-0430.","DOI":"10.1158\/1535-7163.MCT-20-0430"},{"issue":"8","key":"10.1016\/j.bcp.2025.117275_b0470","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.bmc.2016.03.009","article-title":"Design and evaluation of novel glutaminase inhibitors","volume":"24","author":"McDermott","year":"2016","journal-title":"Bioorg. Med. Chem."},{"issue":"10","key":"10.1016\/j.bcp.2025.117275_b0475","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1074\/jbc.M117.810101","article-title":"Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism","volume":"293","author":"Huang","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2025.117275_b0480","unstructured":"L.K. Soth M, Liu G, Burke J, Kovacs J, Bardenhagen J et al, Discovery of IACS-6274: A potent, selective GLS1 inhibitor with excellent pharmacokinetic properties under development for cancers with specific metabolic vulnerabilitie, Abstracts of Papers of the American Chemical Society (2018) 255."},{"key":"10.1016\/j.bcp.2025.117275_b0485","doi-asserted-by":"crossref","unstructured":"T.A. Yap, E.E. Dumbrava, J.R. Ahnert, D.S. Hong, S. Pant, D.D. Karp, S.A.A. Piha-Paul, V. Subbiah, A.M. Tsimberidou, S. Fu, F. Janku, S. Montez, M.T. Ahmad-Taha, D. Guerrero, N.N. Nazarenko, Y. Moore, M. Soth, J. Kovacs, T.P. Heffernan, P. Jones, First-in-human biomarker-driven phase I trial of the potent and selective glutaminase-1 (GLS1) inhibitor IACS-6274 (IPN60090) in patients (pts) with molecularly selected advanced solid tumors, 39(15_suppl) (2021) 3001-3001. doi:10.1200\/JCO.2021.39.15_suppl.3001.","DOI":"10.1200\/JCO.2021.39.15_suppl.3001"},{"issue":"13","key":"10.1016\/j.bcp.2025.117275_b0490","doi-asserted-by":"crossref","first-page":"5599","DOI":"10.1021\/acs.jmedchem.7b00282","article-title":"Design, synthesis, and evaluation of thiazolidine-2,4-dione derivatives as a novel class of glutaminase inhibitors","volume":"60","author":"Yeh","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117275_b0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115014","article-title":"Design, synthesis, and biological evaluation of novel glutaminase 1 allosteric inhibitors with an alkane chain tail group","volume":"246","author":"Chang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117275_b0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114337","article-title":"Discovery of novel glutaminase 1 allosteric inhibitor with 4-piperidinamine linker and aromatic heterocycles","volume":"236","author":"Xu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bcp.2025.117275_b0505","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1021\/acs.jmedchem.0c02044","article-title":"Structure-enabled discovery of novel macrocyclic inhibitors targeting glutaminase 1 allosteric binding site","volume":"64","author":"Xu","year":"2021","journal-title":"J. Med. Chem."},{"issue":"14","key":"10.1016\/j.bcp.2025.117275_b0510","doi-asserted-by":"crossref","first-page":"6540","DOI":"10.1021\/acs.jmedchem.9b00260","article-title":"Discovery of a thiadiazole-pyridazine-based allosteric glutaminase 1 inhibitor series that demonstrates oral bioavailability and activity in tumor xenograft models","volume":"62","author":"Finlay","year":"2019","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2025.117275_b0515","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2024.2430424","article-title":"Butyrate reduces epithelial barrier dysfunction induced by the foodborne mycotoxin deoxynivalenol in cell monolayers derived from pig jejunum organoids","volume":"16","author":"Alberge","year":"2024","journal-title":"Gut Microbes"},{"issue":"1","key":"10.1016\/j.bcp.2025.117275_b0520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcmgh.2019.12.006","article-title":"Increased glutaminolysis marks active scarring in nonalcoholic steatohepatitis progression","volume":"10","author":"Du","year":"2020","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bcp.2025.117275_b0525","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2022.10.007","article-title":"Glutaminase 1 blockade alleviates nonalcoholic steatohepatitis via promoting proline metabolism","volume":"634","author":"Tu","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.bcp.2025.117275_b0530","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s42255-020-0195-8","article-title":"Identifying strategies to target the metabolic flexibility of tumours","volume":"2","author":"M\u00e9ndez-Lucas","year":"2020","journal-title":"Nat Metab"},{"issue":"5","key":"10.1016\/j.bcp.2025.117275_b0535","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/pcn.12639","article-title":"Understanding the roles of glutamine synthetase, glutaminase, and glutamate decarboxylase autoantibodies in imbalanced excitatory\/inhibitory neurotransmission as etiological mechanisms of autism","volume":"72","author":"Hamed","year":"2018","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"10","key":"10.1016\/j.bcp.2025.117275_b0540","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1002\/cam4.2965","article-title":"ASCT2 overexpression is associated with poor survival of OSCC patients and ASCT2 knockdown inhibited growth of glutamine-addicted OSCC cells","volume":"9","author":"Luo","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.bcp.2025.117275_b0545","doi-asserted-by":"crossref","unstructured":"L. Dang, D.W. White, S. Gross, B.D. Bennett, M.A. Bittinger, E.M. Driggers, V.R. Fantin, H.G. Jang, S. Jin, M.C. Keenan, K.M. Marks, R.M. Prins, P.S. Ward, K.E. Yen, L.M. Liau, J.D. Rabinowitz, L.C. Cantley, C.B. Thompson, M.G. Vander Heiden, S.M. Su, Cancer-associated IDH1 mutations produce 2-hydroxyglutarate, Nature 462(7274) (2009) 739-44. doi:10.1038\/nature08617.","DOI":"10.1038\/nature08617"},{"key":"10.1016\/j.bcp.2025.117275_b0550","doi-asserted-by":"crossref","unstructured":"S.K. McBrayer, J.R. Mayers, G.J. DiNatale, D.D. Shi, J. Khanal, A.A. Chakraborty, K.A. Sarosiek, K.J. Briggs, A.K. Robbins, T. Sewastianik, S.J. Shareef, B.A. Olenchock, S.J. Parker, K. Tateishi, J.B. Spinelli, M. Islam, M.C. Haigis, R.E. Looper, K.L. Ligon, B.E. Bernstein, R.D. Carrasco, D.P. Cahill, J.M. Asara, C.M. Metallo, N.H. Yennawar, M.G. Vander Heiden, W.G. Kaelin, Jr., Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma, Cell 175(1) (2018) 101-116.e25. doi:10.1016\/j.cell.2018.08.038.","DOI":"10.1016\/j.cell.2018.08.038"},{"issue":"12","key":"10.1016\/j.bcp.2025.117275_b0555","doi-asserted-by":"crossref","first-page":"e2511","DOI":"10.1038\/cddis.2016.404","article-title":"Dual targeting of glutaminase 1 and thymidylate synthase elicits death synergistically in NSCLC","volume":"7","author":"Lee","year":"2016","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.bcp.2025.117275_b0560","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1172\/JCI78239","article-title":"Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment","volume":"125","author":"Tanaka","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.bcp.2025.117275_b0565","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195151","article-title":"Sulfasalazine, an inhibitor of the cystine-glutamate antiporter, reduces DNA damage repair and enhances radiosensitivity in murine B16F10 melanoma","volume":"13","author":"Nagane","year":"2018","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.bcp.2025.117275_b0570","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.bmcl.2015.12.031","article-title":"2-Amino-4-bis(aryloxybenzyl)aminobutanoic acids: a novel scaffold for inhibition of ASCT2-mediated glutamine transport","volume":"26","author":"Schulte","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"8","key":"10.1016\/j.bcp.2025.117275_b0575","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.trecan.2021.04.003","article-title":"Enhancing the efficacy of glutamine metabolism inhibitors in cancer therapy","volume":"7","author":"Yang","year":"2021","journal-title":"Trends Cancer"},{"issue":"9","key":"10.1016\/j.bcp.2025.117275_b0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111744","article-title":"Inhibition of glutaminolysis restores mitochondrial function in senescent stem cells","volume":"41","author":"Choudhury","year":"2022","journal-title":"Cell Rep."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225005404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225005404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T08:33:02Z","timestamp":1761381182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225005404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":116,"alternative-id":["S0006295225005404"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117275","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glutaminase 1 inhibitors: Therapeutic potential, mechanisms of action, and clinical perspectives","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117275","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117275"}}